PMID- 23668926
OWN - NLM
STAT- MEDLINE
DCOM- 20140417
LR  - 20211203
IS  - 1000-467X (Print)
IS  - 1944-446X (Electronic)
IS  - 1944-446X (Linking)
VI  - 32
IP  - 8
DP  - 2013 Aug
TI  - Dysregulation of mTOR activity through LKB1 inactivation.
PG  - 427-33
LID - 10.5732/cjc.013.10086 [doi]
AB  - Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer 
      types, and two rapamycin derivatives are currently approved by the Food and Drug 
      Administration (FDA) of the United States for treating renal cell carcinoma. 
      Mechanistically, mTOR is hyperactivated in human cancers either due to the 
      genetic activation of its upstream activating signaling pathways or the genetic 
      inactivation of its negative regulators. The tumor suppressor liver kinase B1 
      (LKB1), also known as serine/threonine kinase 11 (STK11), is involved in cell 
      polarity, cell detachment and adhesion, tumor metastasis, and energetic stress 
      response. A key role of LKB1 is to negatively regulate the activity of mTOR 
      complex 1 (mTORC1). This review summarizes the molecular basis of this negative 
      interaction and recent research progress in this area.
FAU - Zhou, Wei
AU  - Zhou W
AD  - The Winship Cancer Institute, Department of Hematology and Oncology, Department 
      of Pathology and Laboratory Medicine, Emory University School of Medicine, 
      Atlanta, GA 30322, USA. wzhou2@emory.edu.
FAU - Marcus, Adam I
AU  - Marcus AI
FAU - Vertino, Paula M
AU  - Vertino PM
LA  - eng
GR  - P01 CA116676/CA/NCI NIH HHS/United States
GR  - R01 CA140571/CA/NCI NIH HHS/United States
GR  - P01-CA116676/CA/NCI NIH HHS/United States
GR  - R01-CA140571/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20130514
PL  - England
TA  - Chin J Cancer
JT  - Chinese journal of cancer
JID - 101498232
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Tuberous Sclerosis Complex 1 Protein)
RN  - 0 (Tuberous Sclerosis Complex 2 Protein)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (STK11 protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.3 (AMP-Activated Protein Kinase Kinases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - AMP-Activated Protein Kinase Kinases
MH  - AMP-Activated Protein Kinases/metabolism
MH  - Adenocarcinoma/drug therapy/metabolism
MH  - Animals
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - Disease Models, Animal
MH  - Endometrial Neoplasms/drug therapy/metabolism
MH  - Female
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Multiprotein Complexes/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Serine-Threonine Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - *Signal Transduction
MH  - Sirolimus/therapeutic use
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Tuberous Sclerosis Complex 1 Protein
MH  - Tuberous Sclerosis Complex 2 Protein
MH  - Tumor Suppressor Proteins/metabolism
PMC - PMC3845579
EDAT- 2013/05/15 06:00
MHDA- 2014/04/18 06:00
PMCR- 2013/08/01
CRDT- 2013/05/15 06:00
PHST- 2013/05/15 06:00 [entrez]
PHST- 2013/05/15 06:00 [pubmed]
PHST- 2014/04/18 06:00 [medline]
PHST- 2013/08/01 00:00 [pmc-release]
AID - cjc.013.10086 [pii]
AID - cjc-32-08-427 [pii]
AID - 10.5732/cjc.013.10086 [doi]
PST - ppublish
SO  - Chin J Cancer. 2013 Aug;32(8):427-33. doi: 10.5732/cjc.013.10086. Epub 2013 May 
      14.